Companies › Locate Bio
2 active drug programs in 3 registered trials: 3 Phase 1; Other; next expected readout Oct 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| LDGraft b-TCP/rhBMP-2 bone graft substitute | – | Phase 1 | Degenerative Disc Disease Lumbar | Oct 2027 |
| LDGraft 0.5mg/cc rhBMP-2 Recombinant human bone morphogenetic protein-2 (rhBMP-2) bone graft substitute | BMP2 | Phase 1 | Degenerative Disc Disease | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07858643 | LDGraft | Phase 1 | Degenerative Disc Disease Lumbar | Other | Oct 2027 |
| NCT06462729 | LDGraft 0.5mg/cc rhBMP-2 | Phase 1 | Degenerative Disc Disease | Other | Dec 2027 |
| NCT06462729 | LDGraft 0.5mg/cc rhBMP-2 | Phase 1 | Degenerative Disc Disease | Other | Dec 2027 |
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.